Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies - PACE-CME

Novel strategies targeting residual risk The promise of PCSK inhibiting therapies

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Heart Failure news from ESC 2016 at a glance
Heart Failure news from ESC 2016 at a glance
ESC 2016
Heart Failure news from ESC 2016 at a glance
- Prof. Mariell Jessup
Epigenetics: A closer look at BET inhibition
Epigenetics: A closer look at BET inhibition
ESC 2016
Epigenetics: A closer look at BET inhibition
No indication for difference in efficacy between potent platelet inhibitors after PCI
No indication for difference in efficacy between potent platelet inhibitors after PCI
ESC 2016
No indication for difference in efficacy between potent platelet inhibitors after PCI
- Steen Dalby Kristensen, MD
Heart failure news at the ESC
Heart failure news at the ESC
ESC 2016
Heart failure news at the ESC
- Frank Ruschitzka, MD